SG11201900680PA - Triple combination of histamine-3 receptor inverse agonists, acetylcholinesterase inhibitors and nmda receptor antagonist - Google Patents
Triple combination of histamine-3 receptor inverse agonists, acetylcholinesterase inhibitors and nmda receptor antagonistInfo
- Publication number
- SG11201900680PA SG11201900680PA SG11201900680PA SG11201900680PA SG11201900680PA SG 11201900680P A SG11201900680P A SG 11201900680PA SG 11201900680P A SG11201900680P A SG 11201900680PA SG 11201900680P A SG11201900680P A SG 11201900680PA SG 11201900680P A SG11201900680P A SG 11201900680PA
- Authority
- SG
- Singapore
- Prior art keywords
- road
- hyderabad
- serene
- telangana
- avenue
- Prior art date
Links
- 229940099433 NMDA receptor antagonist Drugs 0.000 title abstract 3
- 239000000544 cholinesterase inhibitor Substances 0.000 title abstract 3
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 title abstract 3
- 239000002469 receptor inverse agonist Substances 0.000 title abstract 2
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229940125425 inverse agonist Drugs 0.000 abstract 2
- 102000012440 Acetylcholinesterase Human genes 0.000 abstract 1
- 108010022752 Acetylcholinesterase Proteins 0.000 abstract 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 1
- 241000269435 Rana <genus> Species 0.000 abstract 1
- 239000004783 Serene Substances 0.000 abstract 1
- 229940022698 acetylcholinesterase Drugs 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N serine Chemical compound OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641028165 | 2016-08-18 | ||
| PCT/IB2017/054939 WO2018033848A1 (fr) | 2016-08-18 | 2017-08-14 | Triple combinaison d'agonistes inverses du récepteur d'histamine-3, d'inhibiteurs de l'acétylcholinestérase et d'antagonistes du récepteurs nmda |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900680PA true SG11201900680PA (en) | 2019-02-27 |
Family
ID=59829422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900680PA SG11201900680PA (en) | 2016-08-18 | 2017-08-14 | Triple combination of histamine-3 receptor inverse agonists, acetylcholinesterase inhibitors and nmda receptor antagonist |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20190336509A1 (fr) |
| EP (1) | EP3500306B1 (fr) |
| JP (1) | JP6734469B2 (fr) |
| KR (1) | KR102040639B1 (fr) |
| CN (1) | CN109562180B (fr) |
| AU (1) | AU2017311666B2 (fr) |
| BR (1) | BR112019002637A2 (fr) |
| CA (1) | CA3033050C (fr) |
| CY (1) | CY1123522T1 (fr) |
| DK (1) | DK3500306T3 (fr) |
| EA (1) | EA036480B1 (fr) |
| ES (1) | ES2818898T3 (fr) |
| HR (1) | HRP20201511T1 (fr) |
| HU (1) | HUE051474T2 (fr) |
| IL (1) | IL264405B (fr) |
| LT (1) | LT3500306T (fr) |
| MA (1) | MA45988B1 (fr) |
| MD (1) | MD3500306T2 (fr) |
| MX (1) | MX2019001698A (fr) |
| PL (1) | PL3500306T3 (fr) |
| PT (1) | PT3500306T (fr) |
| RS (1) | RS60832B1 (fr) |
| SG (1) | SG11201900680PA (fr) |
| SI (1) | SI3500306T1 (fr) |
| WO (1) | WO2018033848A1 (fr) |
| ZA (1) | ZA201900436B (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA52850A (fr) * | 2018-05-31 | 2021-04-21 | Suven Life Sciences Ltd | Méthode de traitement avec un agoniste inverse du récepteur de l'histamine-3 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2694492T3 (en) * | 2011-02-23 | 2015-11-09 | Suven Life Sciences Ltd | NOVEL COMPOUNDS AS HISTAMINE H3 receptor ligands |
| FR2974729B1 (fr) * | 2011-05-02 | 2013-04-19 | Servier Lab | Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent |
| HUP1300139A2 (en) * | 2013-03-06 | 2014-09-29 | Richter Gedeon Nyrt | Phenoxypiperidine h3 antagonists |
-
2017
- 2017-08-14 PL PL17764658T patent/PL3500306T3/pl unknown
- 2017-08-14 RS RS20201135A patent/RS60832B1/sr unknown
- 2017-08-14 CA CA3033050A patent/CA3033050C/fr active Active
- 2017-08-14 WO PCT/IB2017/054939 patent/WO2018033848A1/fr unknown
- 2017-08-14 DK DK17764658.5T patent/DK3500306T3/da active
- 2017-08-14 SG SG11201900680PA patent/SG11201900680PA/en unknown
- 2017-08-14 LT LTEP17764658.5T patent/LT3500306T/lt unknown
- 2017-08-14 PT PT177646585T patent/PT3500306T/pt unknown
- 2017-08-14 ES ES17764658T patent/ES2818898T3/es active Active
- 2017-08-14 CN CN201780048908.1A patent/CN109562180B/zh not_active Expired - Fee Related
- 2017-08-14 MX MX2019001698A patent/MX2019001698A/es active IP Right Grant
- 2017-08-14 HU HUE17764658A patent/HUE051474T2/hu unknown
- 2017-08-14 EA EA201990481A patent/EA036480B1/ru unknown
- 2017-08-14 JP JP2019506623A patent/JP6734469B2/ja not_active Expired - Fee Related
- 2017-08-14 EP EP17764658.5A patent/EP3500306B1/fr active Active
- 2017-08-14 SI SI201730420T patent/SI3500306T1/sl unknown
- 2017-08-14 MD MDE20190713T patent/MD3500306T2/ro unknown
- 2017-08-14 MA MA45988A patent/MA45988B1/fr unknown
- 2017-08-14 KR KR1020197007052A patent/KR102040639B1/ko active IP Right Grant
- 2017-08-14 US US16/319,668 patent/US20190336509A1/en not_active Abandoned
- 2017-08-14 AU AU2017311666A patent/AU2017311666B2/en not_active Ceased
- 2017-08-14 BR BR112019002637A patent/BR112019002637A2/pt not_active IP Right Cessation
-
2019
- 2019-01-22 ZA ZA2019/00436A patent/ZA201900436B/en unknown
- 2019-01-22 IL IL264405A patent/IL264405B/en active IP Right Grant
-
2020
- 2020-09-21 HR HRP20201511TT patent/HRP20201511T1/hr unknown
- 2020-09-22 CY CY20201100891T patent/CY1123522T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901525XA (en) | Muscarinic m1 receptor positive allosteric modulators | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201900799XA (en) | Pyridopyrimdinone cdk2/4/6 inhibitors | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900269XA (en) | Channel sensing for independent links | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201810765PA (en) | Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201906413XA (en) | Exposure apparatus | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201906164RA (en) | Bicyclic inhibitors of histone deacetylase | |
| SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate |